Instrument NameUnited TherapeuticInstrument Symbol(UTHR-Q)

Instrument ExchangeNASDAQ

Whether you'd like to invest like Nancy Pelosi or Ted Cruz, you can. But maybe you shouldn't.

The Chart of the Day belongs to the pharmaceutical company United Therapeutics (UTHR) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Stocks that traded heavily or had substantial price changes on Monday: United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.61%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.88%. Stock indexes this morning are lower after Fitch Ratings’ downgrade of U.S. government debt spurred a risk-off sentiment in stocks. Stocks are also under pressure...

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million,...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023.

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that recent research across its development portfolio will be presented at the International Society for Heart and Lung Transplantation ( ISHLT ) 43 rd...

We are looking for U.S. health care stocks benefiting as the sector is making gains

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat...

Morning Markets March S&P 500 futures (ESH2 3) this morning are up +0.16%, and March Nasdaq 100 E-Mini futures (NQH2 3) are up +0.25%. U.S. stock index futures this morning are moderately higher on some short covering ahead of this afternoon’s release of the minutes of the Jan 31-Feb 1...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023.

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41 st ...

United Therapeutics (Nasdaq: UTHR ), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2023. This award is presented by Newsweek and Statista Inc., the...

December S&P 500 futures (ESZ22) are trending down -0.30% this morning after three major US benchmark indices closed mixed on Friday as the November payrolls report fueled expectations the Federal Reserve would maintain its path of interest rate hikes to tame inflation.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million,...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization ( WHO ) Group 1 pulmonary arterial...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding...

Investors were obviously cheered by a round of insider buying.